Relay Therapeutics
RLAY
177 hedge funds and large institutions have $1.41B invested in Relay Therapeutics in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 55 increasing their positions, 57 reducing their positions, and 25 closing their positions.
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
28% more capital invested
Capital invested by funds: $1.1B → $1.41B (+$312M)
3% more funds holding
Funds holding: 172 → 177 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 57
3% less ownership
Funds ownership: 106.82% → 103.82% (-3%)
28% less call options, than puts
Call options by funds: $72K | Put options by funds: $100K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$13.5M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$13.2M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$11.4M |
| 4 |
BlackRock
New York
|
+$10.5M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$8.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$35M |
| 2 |
PA
Perceptive Advisors
New York
|
-$16.3M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$12.2M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.31M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.16M |
RLAY Hedge Fund Activity: Q4 2023 in Review
177 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q4 2023, worth a combined $1.41B — up 28% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new RLAY positions and 25 closed out — a net gain of 8 holders — while 55 added to existing stakes and 57 trimmed.
The largest buyer was BVF Inc, adding an estimated $13.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $35M sold.
- 177 institutional investors held Relay Therapeutics (RLAY) as of Q4 2023, up from 172 in Q3 2023.
- Funds reported $1.41B of Relay Therapeutics stock for Q4 2023, up 28% quarter-over-quarter.
- 33 funds opened new Relay Therapeutics positions in Q4 2023 and 25 closed out, a net change of +8 holders.
- The largest Relay Therapeutics buyer in Q4 2023 was BVF Inc, an estimated $13.5M added.
- The largest Relay Therapeutics seller in Q4 2023 was EcoR1 Capital, an estimated $35M sold.
Based on aggregated 13F filings for Q4 2023.